WealthOne’s Gilead Sciences GILD Stock Holding History

WealthOne’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,644	Closed	-$204K	–	91
2023 Q2	$204K	Buy	+2,644	New	+$211K	0.07%	108
2019 Q1	–	Sell	-431	Closed	-$27K	–	249
2018 Q4	$27K	Buy	+431	New	+$30.1K	0.02%	238

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

WealthOne's GILD Position: Q3 2023 in Review

WealthOne sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 2,644 shares — an estimated $204K sold.

WealthOne first reported a position in GILD in Q4 2018 and held it in 2 quarters. The position peaked at $204K in Q2 2023. 1,683 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

WealthOne reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
WealthOne sold 2,644 Gilead Sciences shares in Q3 2023, an estimated $204K.
WealthOne first reported a position in Gilead Sciences in Q4 2018 and held it in 2 quarters.
WealthOne's Gilead Sciences position peaked at $204K in Q2 2023.
1,683 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on WealthOne's 13F filing for Q3 2023, filed 12 Oct 2023.